NASDAQ:TLSIW TriSalus Life Sciences (TLSIW) Stock Price, News & Analysis $1.40 -0.27 (-16.17%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends About TriSalus Life Sciences Stock (NASDAQ:TLSIW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$1.40▼$1.6350-Day Range$0.91▼$1.8652-Week Range$0.81▼$2.24Volume2,953 shsAverage Volume4,450 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More… Receive TLSIW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSIW Stock News HeadlinesLake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationFebruary 14, 2025 | msn.comTriSalus Life Sciences Announces Key Appointments to Board of DirectorsFebruary 3, 2025 | finance.yahoo.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.February 22, 2025 | Brownstone Research (Ad)TriSalus Life Sciences bolsters board with two new membersFebruary 3, 2025 | msn.comTriSalus Life Sciences expands board, appoints new directorsFebruary 2, 2025 | msn.comTrisalus life sciences CEO buys $50,302 in stockJanuary 30, 2025 | msn.comTrisalus life sciences director Sean Murphy buys $157,200 in stockJanuary 30, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Align Tech (ALGN), TriSalus Life Sciences (TLSI)January 24, 2025 | markets.businessinsider.comSee More Headlines TLSIW Stock Analysis - Frequently Asked Questions How have TLSIW shares performed this year? TriSalus Life Sciences' stock was trading at $1.10 at the beginning of 2025. Since then, TLSIW shares have increased by 27.3% and is now trading at $1.40. View the best growth stocks for 2025 here. How do I buy shares of TriSalus Life Sciences? Shares of TLSIW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSIW CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$26.89 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:TLSIW) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.